What is Achilles Therapeutics PLC (ACHL)?

Aktienanalyse zu Achilles Therapeutics PLC (ACHL)

$1.480

+0.010 (+0.68%)Zum Schluss

Loading chart…

High: 1.500
Open: 1.480
VWAP: 1.48
Vol: 1.20M
Mkt Cap: 34.59M
Low: 1.445
Amount: 1.78M
EV/EBITDA, TTM: 0.22

Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.

www.achillestx.com

Bewertungskennzahlen

The current forward P/E ratio for Achilles Therapeutics PLC (ACHL) is -12.25, compared to its 5-year average forward P/E of -1.72.

Forward P/E

Strongly Undervalued

5Y Average P/E

-1.72

Current P/E

-12.25

Überbewertet

0.48

Unterbewertet

-3.93

Forward EV/EBITDA

Undervalued

5Y Average EV/EBITDA

1.14

Current EV/EBITDA

0.22

Überbewertet

1.78

Unterbewertet

0.49

Forward P/S

Strongly Undervalued

5Y Average P/S

0.00

Current P/S

0.00

Überbewertet

0.00

Unterbewertet

0.00

Event-Zeitleiste

2025-02-28 (ET)